

**Overview****Useful For**

Diagnosis of brucellosis

**Method Name**

Agglutination

**NY State Available**

Yes

**Specimen****Specimen Type**

Serum

**Specimen Required**

**Supplies:** Sarstedt Aliquot Tube 5 mL (T914)

**Collection Container/Tube:**

**Preferred:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL

**Collection Instructions:** Centrifuge and aliquot serum into a plastic vial.

**Forms**

If not ordering electronically, complete, print, and send [Infectious Disease Serology Test Request](#) (T916) with the specimen.

**Specimen Minimum Volume**

0.25 mL

**Reject Due To**

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	OK

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	14 days	
	Frozen	14 days	

## Clinical & Interpretive

### Clinical Information

*Brucella* species are facultative intracellular, gram-negative bacilli that cause brucellosis in humans. Human disease is likely acquired by contact with animals infected with the organism (*Brucella abortus*, *Brucella suis*, *Brucella melitensis*, and occasionally *Brucella canis*) either by direct contact or by ingestion of meat or milk. The signs and symptoms associated with brucellosis may include fever, night sweats, chills, weakness, malaise, headache, and anorexia. The physical examination may reveal lymphadenopathy and hepatosplenomegaly. A definitive diagnosis of brucellosis is made by recovering the organism from bone marrow, blood, fluid (including urine), or tissue specimens.

In cases of suspected brucellosis, serology may assist in the diagnosis and play a supplementary role in routine culture. Antibodies to *Brucella* species may not become detectable until 1 to 2 weeks following the onset of symptoms, so serum specimens collected during acute disease may be negative by serology in patients with brucellosis. If serology is performed, the Centers for Disease Control and Prevention currently recommends that specimens testing positive or equivocal for IgG or IgM by a screening enzyme immunoassay be confirmed by a *Brucella*-specific agglutination method.

### Reference Values

<1:80

### Interpretation

The Centers for Disease Control and Prevention recommends that specimens testing positive or equivocal for IgG or IgM by a screening enzyme immunoassay (EIA) be confirmed by a *Brucella*-specific agglutination method.

Titers below 1:80 are seen in normal, healthy populations. Titers of 1:80 or greater are often considered clinically significant (1); however, a 4-fold or greater increase in titers between acute and convalescent phase sera is required to diagnose acute infection.

Positive results by a screening EIA that are not confirmed by *Brucella*-specific agglutination may represent false-positive screening results. If clinically indicated, a new specimen should be tested after 7 to 14 days.

### Cautions

The tube agglutination assay was designed using antigen derived from *Brucella abortus* and may not be positive in patients infected with other *Brucella* species (eg, *Brucella canis*).

Positive results by *Brucella* serology are not diagnostic of acute infection, as antibodies may persist for months to years following exposure. To diagnose acute infection, detection of *Brucella* species in culture is the recommended approach (see BRUCB / *Brucella* Culture, Blood).

*Brucella abortus* strain RB51 is used for vaccination of animals in the United States. There are currently no serologic tests to detect an antibody response to strain RB51 in humans. Per Centers for Disease Control and Prevention guidelines, routine clinical serology tests for *Brucella* do not detect an antibody response to strain RB51. Note that other strains besides RB51 may be used for vaccinating animals outside of the United States.(2)

**Clinical Reference**

1. Welch RJ, Litwin CM. A comparison of *Brucella* IgG and IgM ELISA assays with agglutination methodology. *J Clin Lab Anal.* 2010;24(3):160-162
2. Gunes H, Dogan M False-positivity in diagnosis of brucellosis associated with Rev-1 vaccine. *Libyan J Med.* 2013;8:10.3402/ljm.v8i0.20417
3. Stoddard RA. Detection of *Brucella* spp antibodies. In: Leber AL, Burnham CD, eds. *Clinical Microbiology Procedures Handbook*. 5th ed. AMS Press; 2023:section13.3.3

**Performance****Method Description**

Serially diluted serum is added to an antigen prepared from *Brucella abortus* strain 1119-3. Agglutination or flocculation is assessed after incubation at 37 degrees C for 48 hours.(Package insert: Animal and Plant Health Inspection Service National Veterinary Services Laboratories, Kirsh D. US Dept of Health, Education, and Welfare; 1973; Cooke FJ, Slack MPE. Gram-negative coccobacilli. In: Cohen J, Powderly WG, Opal SM, eds. *Infectious Diseases*. 4th ed. Elsevier; 2017:1611-1627)

**PDF Report**

No

**Day(s) Performed**

Wednesday, Friday

**Report Available**

2 to 7 days

**Specimen Retention Time**

14 days

**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Superior Drive

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.

- 
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
  - Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

**CPT Code Information**

86622

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
BRUTA	Brucella Ab, Agglutination, S	19053-8

Result ID	Test Result Name	Result LOINC® Value
8112	Brucella Ab, Agglutination, S	In Process